Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer

Abstract

Multiple randomized studies have shown that combination of chemotherapy and immune checkpoint inhibitors (ICIs) leads to better response rates and survival as compared to chemotherapy alone in the advanced stage of NSCLC. Data suggesting a benefit to using ICIs in the neoadjuvant therapy of patients with early stage NSCLC are emerging. Eligible subjects were treatment naïve patients with stage IB, II, and resectable IIIA NSCLC. Patients received three cycles of neoadjuvant chemotherapy with four doses of avelumab every 2 weeks. Patients with squamous cell cancer received cisplatin or carboplat

Abstract by Arafat Tfayli; Majd Al Assaad; Ghina Fakhri; Reem Akel; Hanine Atwi; Hady Ghanem; Fadi El Karak; Fadi Farhat, Cancer Medicine (2020) — licensed CC BY 4.0.

Related failures